Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt No Debt
NAS:GALT's Cash-to-Debt is ranked higher than
99% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. NAS:GALT: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:GALT' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.59  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
NAS:GALT's Interest Coverage is ranked higher than
99% of the 635 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 105.95 vs. NAS:GALT: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NAS:GALT' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 2
Altman Z-Score: -6.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE % -190.71
NAS:GALT's ROE % is ranked lower than
96% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. NAS:GALT: -190.71 )
Ranked among companies with meaningful ROE % only.
NAS:GALT' s ROE % Range Over the Past 10 Years
Min: -1658.88  Med: -153.68 Max: -107.68
Current: -190.71
-1658.88
-107.68
ROA % -107.88
NAS:GALT's ROA % is ranked lower than
95% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. NAS:GALT: -107.88 )
Ranked among companies with meaningful ROA % only.
NAS:GALT' s ROA % Range Over the Past 10 Years
Min: -1309.12  Med: -143.39 Max: -71.42
Current: -107.88
-1309.12
-71.42
3-Year EBITDA Growth Rate 0.80
NAS:GALT's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. NAS:GALT: 0.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:GALT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -4.6 Max: 11.4
Current: 0.8
0
11.4
3-Year EPS without NRI Growth Rate -16.40
NAS:GALT's 3-Year EPS without NRI Growth Rate is ranked lower than
78% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. NAS:GALT: -16.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:GALT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -33.7  Med: -5 Max: 36.2
Current: -16.4
-33.7
36.2
GuruFocus has detected 3 Warning Signs with Galectin Therapeutics Inc $NAS:GALT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:GALT's 10-Y Financials

Financials (Next Earnings Date: 2017-08-09 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with GALT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:AGRX, OTCPK:GRMD, NAS:ARLZ, OTCPK:HYYDF, OTCPK:ORXOY, OTCPK:ACNNF, NAS:TYHT, NAS:CPIX, NAS:MSLI, OTCPK:CPHRF, NAS:DRRX, NAS:ADMP, OTCPK:BIOYF, NAS:LPCN, OTCPK:ZOMHF, NAS:SPHS, NAS:IMMY, NAS:SCYX, OTCPK:OWCP, NAS:SMMT » details
Traded in other countries:PHPN.Germany,
Headquarter Location:USA
Galectin Therapeutics Inc is a clinical stage biopharmaceutical company. The Company is engaged in drug research and development to create new therapies for fibrotic disease and cancer.

Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galectin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.

Ratios

vs
industry
vs
history
PB Ratio 32.21
GALT's PB Ratio is ranked lower than
97% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. GALT: 32.21 )
Ranked among companies with meaningful PB Ratio only.
GALT' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 457.5
Current: 32.21
0
457.5
EV-to-EBIT -4.47
GALT's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. GALT: -4.47 )
Ranked among companies with meaningful EV-to-EBIT only.
GALT' s EV-to-EBIT Range Over the Past 10 Years
Min: -4.77  Med: 0 Max: 0
Current: -4.47
-4.77
0
EV-to-EBITDA -4.48
GALT's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. GALT: -4.48 )
Ranked among companies with meaningful EV-to-EBITDA only.
GALT' s EV-to-EBITDA Range Over the Past 10 Years
Min: -4.77  Med: 0 Max: 0
Current: -4.48
-4.77
0
Current Ratio 4.18
GALT's Current Ratio is ranked higher than
71% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. GALT: 4.18 )
Ranked among companies with meaningful Current Ratio only.
GALT' s Current Ratio Range Over the Past 10 Years
Min: 0.29  Med: 3.45 Max: 20.36
Current: 4.18
0.29
20.36
Quick Ratio 4.18
GALT's Quick Ratio is ranked higher than
76% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. GALT: 4.18 )
Ranked among companies with meaningful Quick Ratio only.
GALT' s Quick Ratio Range Over the Past 10 Years
Min: 0.29  Med: 3.45 Max: 20.36
Current: 4.18
0.29
20.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.50
GALT's 3-Year Average Share Buyback Ratio is ranked lower than
82% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. GALT: -20.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GALT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -26.1  Med: -19.9 Max: -10.6
Current: -20.5
-26.1
-10.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 9.87
GALT's Price-to-Net-Cash is ranked higher than
63% of the 206 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 12.25 vs. GALT: 9.87 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GALT' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 2.69  Med: 13.17 Max: 115.43
Current: 9.87
2.69
115.43
Price-to-Net-Current-Asset-Value 34.00
GALT's Price-to-Net-Current-Asset-Value is ranked lower than
88% of the 443 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.16 vs. GALT: 34.00 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GALT' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.69  Med: 11.96 Max: 161.6
Current: 34
2.69
161.6
Price-to-Tangible-Book 32.21
GALT's Price-to-Tangible-Book is ranked lower than
93% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. GALT: 32.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GALT' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.71  Med: 11.51 Max: 171.91
Current: 32.21
2.71
171.91
Earnings Yield (Greenblatt) % -22.37
GALT's Earnings Yield (Greenblatt) % is ranked lower than
93% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. GALT: -22.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GALT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -25770.33  Med: 0 Max: 4520.18
Current: -22.37
-25770.33
4520.18

More Statistics

EPS (TTM) $ -0.75
Beta2.94
Short Percentage of Float6.25%
52-Week Range $0.49 - 3.68
Shares Outstanding (Mil)34.06

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -0.48 -0.74 -1.03
EPS without NRI ($) -0.48 -0.74 -1.03
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for NAS:GALT

Headlines

Articles On GuruFocus.com
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent f Apr 25 2017 
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver Congr Apr 18 2017 
Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update Mar 28 2017 
Galectin Therapeutics Issues Statement Regarding GALTW and GALTU Mar 23 2017 
Galectin Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Busin Mar 21 2017 
GR-MD-02 Demonstrates Clinically Significant Effect in Patients with Severe and Refractory Atopic De Mar 14 2017 
Galectin Therapeutics to Present at 29th Annual ROTH Conference Mar 09 2017 
Galectin’s GR-MD-02 Demonstrates Efficacy in Patients with Moderate to Severe Plaque Psoriasis Mar 06 2017 
Galectin Therapeutics, Inc. Executive Chairman Jim Czirr to Be Interviewed on "The Big Biz Show" Oct 06 2015 

More From Other Websites
Can The Uptrend Continue for Galectin Therapeutics (GALT)? Apr 28 2017
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent... Apr 25 2017
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings? Apr 24 2017
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings? Apr 24 2017
Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store? Apr 20 2017
Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings? Apr 20 2017
ResMed (RMD) Q3 Earnings: Disappointment in the Cards? Apr 18 2017
IDEXX Laboratories (IDXX) Q1 Earnings: Surprise in Store? Apr 18 2017
Galectin Therapeutics and Exalenz to Present Late-Breaking Abstract at The International Liver... Apr 18 2017
Can Illumina (ILMN) Spring a Surprise this Earnings Season? Apr 17 2017
5 Drug Stocks That Could Be Big Winners this Earnings Season Apr 17 2017
Integra LifeSciences (IART) Q1 Earnings: A Beat in Store? Apr 13 2017
GNC Holdings (GNC) Q1 Earnings: Disappointment in Store? Apr 12 2017
Galectin Therapeutics and Axovant Sciences See Stocks Rise on Investor Optimism Apr 11 2017
Galectin Therapeutics (GALT) Looks Good: Stock Jumps 16.7% Apr 10 2017
Akari Therapeutics, Galectin Therapeutics Receive Positive Financial News Apr 03 2017
Galectin Shares Upgraded To Buy; NASH-CX Results In December A 'Major Stock Catalyst' Mar 30 2017
Edited Transcript of GALT earnings conference call or presentation 28-Mar-17 1:00pm GMT Mar 29 2017
Galectin Therapeutics Reports 2016 Financial Results and Provides Business Update Mar 28 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)